Intellia Therapeutics (NTLA) is back in focus after reporting positive Phase 3 HAELO results for lonvo-z in hereditary angioedema, as well as starting a rolling biologics license application and restarting key ATTR amyloidosis trials.

Despite the latest 1-day share price return falling 8.33% to US$13.09 and the 30-day share price return down 11.43%, the 90-day share price return of 10.28% and year to date share price return of 42.13% suggest momentum has been improving. The 1-year total shareholder return of 62.11% contrasts with longer term total shareholder return declines over three and five years as the market reassesses Intellia’s gene editing pipeline after the HAELO data, BLA progress and resumed ATTR trials.

If gene editing is on your radar, this could be a good moment to see what else is moving in healthcare by scanning 34 healthcare AI stocks

With Intellia’s shares still well below their three and five year levels, yet up sharply over the past year on landmark gene editing results, the key question is simple: is this a genuine discount or is future growth already priced in?

Most Popular Narrative: 51% Undervalued

At a last close of $13.09 versus a narrative fair value of $26.70, the current price sits well below what the most followed view implies, putting the focus squarely on how much faith you place in its growth story and clinical progress.

Improving financial discipline, as evidenced by successful restructuring, declining GAAP operating expenses (~10% reduction YoY), and a robust cash runway into the first half of 2027, enables Intellia to absorb increased R&D investment, advance pipeline expansion, and build out commercial infrastructure without dilutive fundraising, supporting protection of net margins and improving future earnings visibility.

Want to see what kind of revenue ramp and margin shift would need to line up for that valuation gap to close? The narrative leans on rapid top line expansion, a swing from heavy losses to positive earnings, and a future earnings multiple more often associated with mature growth leaders. Curious which assumptions really carry the weight in that fair value number and how sensitive the outcome is to small changes?

Result: Fair Value of $26.70 (UNDERVALUED)

However, the story could change quickly if safety concerns reemerge in key trials or if payer pushback limits uptake for high cost gene editing therapies.

Another Angle: Rich Sales Multiple Versus Peers

The DCF and narrative point to upside, but the market is pricing Intellia differently when you look at sales. The stock trades on a P/S of 27.7x, versus 10.9x for the US Biotechs industry, 29.6x for close peers, and a fair ratio of just 0.1x. That gap suggests either a very optimistic outlook or meaningful downside risk if expectations cool. Which side do you lean toward?

For a closer look at how those sales multiples stack up against what the fair ratio suggests the market could move toward over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With both risks and rewards in play, sentiment around Intellia is clearly mixed. This may be a good time to check the underlying data and stress test your own thesis with the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock. Broader idea hunting can reveal opportunities you would otherwise miss.

• Spot potential turnaround plays early and scan 27 elite penny stocks with strong financials that pair smaller market caps with stronger financial profiles.
• Target quality at a reasonable price and review the 47 high quality undervalued stocks that currently stand out on both fundamentals and valuation.
• Prioritize resilience first and run your eye over the 67 resilient stocks with low risk scores to see which companies score well on financial strength and stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.